愛博醫療(688050.SH):有晶體眼人工晶狀體通過創新醫療器械特別審查程序獲批上市
格隆匯1月7日丨愛博醫療(688050.SH)公佈,公司之“有晶體眼人工晶狀體”於近日通過國家藥品監督管理局創新醫療器械特別審查獲準註冊,有晶體眼人工晶狀體屬於屈光性人工晶狀體,該產品在創新的平衡型丙烯酸酯材料基礎上,採用零球差大光學區設計以及雙凹面型的穩定拱高設計,植入眼內後可作為屈光元件,有效降低/矯正近視,併為患者提供優質的術後視覺質量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.